JNJ-79635322 shows favorable responses and manageable safety in BCMA/GPRC5D-naïve patients with relapsed/refractory multiple ...

First-in-human data for the trispecific antibody “suggest a paradigm shift” for the relapsed/refractory multiple myeloma ...

Monoclonal antibodies might help to elucidate the pathogenesis ... with other immunosuppressive therapies. Rituximab is a chimeric mAb that targets the CD20 antigen on B cells and induces cell ...

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Market Size and Growth: Analysis of the current market size and projections for the cancer monoclonal antibody market from 2023 to 2032. This includes data on market value and volume, as well as the ...

Association between DNA level aberrations and immune cell infiltration in breast cancer. This is an ASCO Meeting Abstract from the 2016 ASCO Annual Meeting I. This abstract does not include a full ...

Adding Blenrep to standard therapy prolonged progression-free survival in patients with relapsed or refractory multiple ...

Monoclonal antibodies (mAbs) have had a significant effect on current practice in oncology. Mechanisms of action include direct tumour cell destruction and indirect targeting of growth and pro ...

Next, anti-CTLA-4 monoclonal antibodies were newly established and characterized for their binding properties and functional blockade of the CTLA-4 axis. A caninized (canine-ized) anti-CTLA-4 antibody ...

the reported MIA methods commonly require multiple antibodies since each antibody can recognize only one antigen. Herein, a novel bispecific monoclonal antibody (BsMcAb) that could bind methyl ...

Two monoclonal antibody targeted therapies have been recommended for routine NHS use in England by the National Institute for Health and Care Excellence (NICE). Spesolimab (Spevigo, Boehringer ...